Value of Antibody Drug Conjugates for Gynecological Cancers: A Modern Appraisal Following Recent FDA Approvals

Abstract

Blair McNamara, Yifan Chang, Ashley Goreshnik, Alessandro D Santin Department of Obstetrics, Gynecology, and Reproductive Sciences Yale University School of Medicine, New Haven, CT, 06520, USACorrespondence: Alessandro D Santin, Obstetrics and Gynecology, Yale University School of Medicine, 333 Cedar Street, PO Box 208063, New Haven, CT, 06520, USA, Tel [phone], Fax [phone], Email [email protected]: Antibody drug conjugates (ADCs) are a new class of targeted anti-cancer therapies that combine a monoclonal tumor surface receptor-targeting antibody with a highly cytotoxic molecule payload. They enable delivery of cytotoxic therapy more directly to tumor cells and minimize delivery to healthy tissues. This review summarizes the existing literature about ADC therapies approved for use in gynecologic malignancies, relevant preclinical studies, as well as ongoing clinical trials.Keywords: antibody-drug conjugate, gynecologic malignancy, chemotherapy, cervical cancer, ovarian cancer, endometrial cancer

Keywords

• antibody-drug conjugate
• gynecologic malignancy
• chemotherapy
• cervical cancer
• ovarian cancer
• endometrial cancer